This inhibition blocks downstream effectors like S6 ribosomal protein and 4EBP1, suppressing tumor cell proliferation, promoting apoptosis, and counteracting hyperactivation caused by oncogenic mutations. The gene discussed is RPS6; the disease is neoplasm.